↓ Skip to main content

Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease

Overview of attention for article published in Journal for Immunotherapy of Cancer, May 2018
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (91st percentile)

Mentioned by

blogs
1 blog
twitter
28 tweeters
patent
1 patent

Citations

dimensions_citation
136 Dimensions

Readers on

mendeley
154 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease
Published in
Journal for Immunotherapy of Cancer, May 2018
DOI 10.1186/s40425-018-0342-x
Pubmed ID
Authors

Michael M. Boyiadzis, John M. Kirkwood, John L. Marshall, Colin C. Pritchard, Nilofer S. Azad, James L. Gulley

Abstract

The U.S. Food and Drug Administration (FDA) recently approved pembrolizumab, an anti- programmed cell death protein 1 cancer immunotherapeutic, for use in advanced solid tumors in patients with the microsatellite-high/DNA mismatch repair-deficient biomarker. This is the first example of a tissue-agnostic FDA approval of a treatment based on a patient's tumor biomarker status, rather than on tumor histology. Here we discuss key issues and implications arising from the biomarker-based disease classification implied by this historic approval.

Twitter Demographics

The data shown below were collected from the profiles of 28 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 154 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 154 100%

Demographic breakdown

Readers by professional status Count As %
Student > Master 27 18%
Student > Bachelor 24 16%
Researcher 20 13%
Student > Ph. D. Student 19 12%
Student > Doctoral Student 10 6%
Other 19 12%
Unknown 35 23%
Readers by discipline Count As %
Medicine and Dentistry 40 26%
Biochemistry, Genetics and Molecular Biology 29 19%
Agricultural and Biological Sciences 14 9%
Immunology and Microbiology 8 5%
Pharmacology, Toxicology and Pharmaceutical Science 6 4%
Other 12 8%
Unknown 45 29%

Attention Score in Context

This research output has an Altmetric Attention Score of 27. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 28 June 2022.
All research outputs
#1,134,740
of 21,673,824 outputs
Outputs from Journal for Immunotherapy of Cancer
#268
of 2,679 outputs
Outputs of similar age
#26,723
of 298,082 outputs
Outputs of similar age from Journal for Immunotherapy of Cancer
#1
of 1 outputs
Altmetric has tracked 21,673,824 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 94th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,679 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 14.3. This one has done well, scoring higher than 89% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 298,082 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 91% of its contemporaries.
We're also able to compare this research output to 1 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them